Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer

Abstract

Biweekly docetaxel and cisplatin with concurrent RT was active and well tolerated in patients with unresectable stage III NSCLC.

Phase II study of a biweekly schedule of docetaxel and cisplatin in patients with metastatic non-small cell lung cancer

“…Thus, the nadir periods do not overlap when the drugs are administered concomitantly. In addition, better safety outcomes have been reported with biweekly administration of docetaxel in patients with NSCLC [33,34], breast cancer [35], stomach cancer [36], and ovarian cancer [37,38]. We considered that biweekly administration of low-dose cisplatin may reduce its toxicity, with adequate hydration in the outpatient clinic, and that avoiding the inconvenience of hospitalization could improve compliance.…”

Phase II Trial of Biweekly Chemotherapy with Docetaxel and Cisplatin in High-Risk Patients with Unresectable Non-Small Cell Lung Cancer

“…Thus, the nadir periods do not overlap when the drugs are administered concomitantly [15]. Additionally, feasible clinical outcomes of biweekly administration of docetaxel in patients with NSCLC [15,16,17], breast cancer [18], stomach cancer [19], ovarian cancer [20,21], and prostate cancer [22,23] with better safety profiles and compliance have been reported.…”

Standard Treatment Option in Stage III Non–Small-Cell Lung Cancer: Case Against Trimodal Therapy and Consolidation Drug Therapy

“…Results of selected phase II studies are listed in Table 2. [37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53] Although some investigators administered a complete treatment package (concurrent and consolidation parts) to all patients, others administered it to patients with noneprogressive disease (PD)-that is, those with complete response (CR), partial response (PR), or stable disease (SD)-while some did so only to patients whose disease responded (CR or PR) to treatment. Interestingly, 2 different treatment strategies can be identified.…”

“…In the first, the same CHT was administered during the concurrent and consolidation phases. [37][38][39]41,42,[44][45][46][47]49 In the second approach, different drugs were used in the consolidation phase. 40,43,48,53 Regardless of these differences, the results of these studies seemed as promising with MSTs ranging from 14.5 to 36 months, while 1-year survivals ranged from 27% to 64% and, although rarely reported, 5-year survivals ranged from 17% to 40%.…”